Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
作者： S Sacchi , H Kantarjian , S O'Brien , P R Cohen , S Pierce
DOI: 10.1200/JCO.1995.13.9.2401
关键词:
摘要: PURPOSELong-term treatment with interferon alfa (IFN alpha) can produce or exacerbate immune-mediated complications (IMC). The purpose of this study was to analyze the experience IMC and unusual in patients chronic myelogenous leukemia (CML) undergoing IFN alpha treatment.PATIENTS AND METHODSThe occurrence evaluated Philadelphia chromosome (Ph)-positive CML.RESULTSWell-documented clinically evident developed 35 after a median 14 months treatment. These included 28 (5%) 581 Ph-positive CML treated alpha-containing regimens at M.D. Anderson Cancer Center (MDACC) seven referred for opinion problems who were on other studies. Hypothyroidism occurred 11 (2%), hemolysis (1%), connective tissue diseases (2%). Other occurrences congestive heart failure (CHF; n = 4), porphyria cutanea tar...
sci-hub.se 参考文章(29)
R Hehlmann, H Heimpel, J Hasford, HJ Kolb, H Pralle, DK Hossfeld, W Queisser, H Loffler, B Heinze, A Georgii, Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group Blood. ,vol. 82, pp. 398- 407 ,(1993) , 10.1182/BLOOD.V82.2.398.398
Sante Tura, Michele Baccarani, Eliana Zuffa, Domenico Russo, Renato Fanin, Alfonso Zaccaria, Mauro Fiacchini, None, Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The New England Journal of Medicine. ,vol. 330, pp. 820- 825 ,(1994) , 10.1056/NEJM199403243301204
H M Golomb, A Jacobs, A Fefer, H Ozer, J Thompson, C Portlock, M Ratain, D Golde, J Vardiman, J S Burke, Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. Journal of Clinical Oncology. ,vol. 4, pp. 900- 905 ,(1986) , 10.1200/JCO.1986.4.6.900
Moshe Sonnenblick, Arnold Rosin, Cardiotoxicity of interferon. A review of 44 cases. Chest. ,vol. 99, pp. 557- 561 ,(1991) , 10.1378/CHEST.99.3.557
E. Toumbis-Ioannou, P. R. Cohen, Chemotherapy-induced Raynaud's phenomenon Cleveland Clinic Journal of Medicine. ,vol. 61, pp. 195- 199 ,(1994) , 10.3949/CCJM.61.3.195
PIA BURMAN, THOMAS H. TÖTTERMAN, K. ÖBERG, F. ANDERS KARLSSON, Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. The Journal of Clinical Endocrinology and Metabolism. ,vol. 63, pp. 1086- 1090 ,(1986) , 10.1210/JCEM-63-5-1086
MAGNUS GIDLUND, ANDERS ÖRN, HANS WIGZELL, ANNA SENIK, ION GRESSER, Enhanced NK cell activity in mice injected with interferon and interferon inducers Nature. ,vol. 273, pp. 759- 761 ,(1978) , 10.1038/273759A0
J. Todd, H Acha-Orbea, J. Bell, N Chao, Z Fronek, C. Jacob, M McDermott, A. Sinha, L Timmerman, L Steinman, al. et, A molecular basis for MHC class II--associated autoimmunity Science. ,vol. 240, pp. 1003- 1009 ,(1988) , 10.1126/SCIENCE.3368786
H. Niizeki, N. Inamoto, K. Nakamura, K. Tsuchimoto, T. Hashimoto, T. Nishikawa, A case of pemphigus foliaceus after interferon alpha-2a therapy. Dermatology. ,vol. 189, pp. 129- 130 ,(1994) , 10.1159/000246954
Kevin C. Conlon, Walter J. Urba, John W. Smithii, Ronald G. Steis, Dan L. Longo, Jeffrey W. Clark, Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy Cancer. ,vol. 65, pp. 2237- 2242 ,(1990) , 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5